Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 31% on Friday . The company traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares were traded during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The firm has a market cap of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a 50 day moving average price of C$0.20 and a two-hundred day moving average price of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Compound Interest and Why It Matters When Investing
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Earnings Per Share Calculator: How to Calculate EPS
- DuPont’s Electronics Spinoff: The Start of Something Big
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
